# F5, Inc.: financial statements, quarterly

FFIV · Nasdaq · CIK 1048695 · [Technology](/sectors/technology.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/ffiv.md) · [Financials](/companies/ffiv/financials.md) · [Filings](/companies/ffiv/filings.md) · [Insiders](/companies/ffiv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ffiv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [707 d](/filings/0001048695-25-000157.md) | [693](/filings/0001048695-25-000026.md) | [681](/filings/0001048695-25-000091.md) | [695](/filings/0001048695-25-000129.md) | [747 d](/filings/0001048695-25-000157.md) | [766](/filings/0001048695-26-000023.md) | [731](/filings/0001048695-26-000051.md) | [780](/filings/0001048695-26-000067.md) | [810 d](/filings/0001048695-25-000157.md) | [822](/filings/0001048695-26-000023.md) | [812](/filings/0001048695-26-000051.md) | [865](/filings/0001048695-26-000067.md) |
| Cost of revenue | $m | [141 d](/filings/0001048695-25-000157.md) | [136](/filings/0001048695-25-000026.md) | [141](/filings/0001048695-25-000091.md) | [136](/filings/0001048695-25-000129.md) | [144 d](/filings/0001048695-25-000157.md) | [141](/filings/0001048695-26-000023.md) | [141](/filings/0001048695-26-000051.md) | [149](/filings/0001048695-26-000067.md) | [144 d](/filings/0001048695-25-000157.md) | [152](/filings/0001048695-26-000023.md) | [151](/filings/0001048695-26-000051.md) | [154](/filings/0001048695-26-000067.md) |
| Gross profit | $m | [566 d](/filings/0001048695-25-000157.md) | [556](/filings/0001048695-25-000026.md) | [540](/filings/0001048695-25-000091.md) | [559](/filings/0001048695-25-000129.md) | [603 d](/filings/0001048695-25-000157.md) | [626](/filings/0001048695-26-000023.md) | [590](/filings/0001048695-26-000051.md) | [632](/filings/0001048695-26-000067.md) | [666 d](/filings/0001048695-25-000157.md) | [671](/filings/0001048695-26-000023.md) | [661](/filings/0001048695-26-000051.md) | [712](/filings/0001048695-26-000067.md) |
| Research and development | $m | [128 d](/filings/0001048695-25-000157.md) | [120](/filings/0001048695-25-000026.md) | [122](/filings/0001048695-25-000091.md) | [124](/filings/0001048695-25-000129.md) | [124 d](/filings/0001048695-25-000157.md) | [131](/filings/0001048695-26-000023.md) | [137](/filings/0001048695-26-000051.md) | [136](/filings/0001048695-26-000067.md) | [136 d](/filings/0001048695-25-000157.md) | [141](/filings/0001048695-26-000023.md) | [151](/filings/0001048695-26-000051.md) | [165](/filings/0001048695-26-000067.md) |
| Operating income | $m | [172 d](/filings/0001048695-25-000157.md) | [165](/filings/0001048695-25-000026.md) | [140](/filings/0001048695-25-000091.md) | [163](/filings/0001048695-25-000129.md) | [191 d](/filings/0001048695-25-000157.md) | [205](/filings/0001048695-26-000023.md) | [159](/filings/0001048695-26-000051.md) | [196](/filings/0001048695-26-000067.md) | [206 d](/filings/0001048695-25-000157.md) | [214](/filings/0001048695-26-000023.md) | [179](/filings/0001048695-26-000051.md) | [213](/filings/0001048695-26-000067.md) |
| Income tax | $m | [22.7 d](/filings/0001048695-25-000157.md) | [36.0](/filings/0001048695-25-000026.md) | [26.9](/filings/0001048695-25-000091.md) | [27.5](/filings/0001048695-25-000129.md) | [38.2 d](/filings/0001048695-25-000157.md) | [42.6](/filings/0001048695-26-000023.md) | [25.7](/filings/0001048695-26-000051.md) | [23.1](/filings/0001048695-26-000067.md) | [24.6 d](/filings/0001048695-25-000157.md) | [42.9](/filings/0001048695-26-000023.md) | [41.5](/filings/0001048695-26-000051.md) | [18.0](/filings/0001048695-26-000067.md) |
| Net income | $m | [152 d](/filings/0001048695-25-000157.md) | [138](/filings/0001048695-25-000026.md) | [119](/filings/0001048695-25-000091.md) | [144](/filings/0001048695-25-000129.md) | [165 d](/filings/0001048695-25-000157.md) | [166](/filings/0001048695-26-000023.md) | [146](/filings/0001048695-26-000051.md) | [190](/filings/0001048695-26-000067.md) | [190 d](/filings/0001048695-25-000157.md) | [180](/filings/0001048695-26-000023.md) | [148](/filings/0001048695-26-000051.md) | [208](/filings/0001048695-26-000067.md) |
| Diluted EPS | $ per share | not reported | [2.32](/filings/0001048695-25-000026.md) | [2.00](/filings/0001048695-25-000091.md) | [2.44](/filings/0001048695-25-000129.md) | not reported | [2.82](/filings/0001048695-26-000023.md) | [2.48](/filings/0001048695-26-000051.md) | [3.25](/filings/0001048695-26-000067.md) | not reported | [3.10](/filings/0001048695-26-000023.md) | [2.58](/filings/0001048695-26-000051.md) | [3.62](/filings/0001048695-26-000067.md) |
| Basic EPS | $ per share | not reported | [2.34](/filings/0001048695-25-000026.md) | [2.02](/filings/0001048695-25-000091.md) | [2.46](/filings/0001048695-25-000129.md) | not reported | [2.85](/filings/0001048695-26-000023.md) | [2.51](/filings/0001048695-26-000051.md) | [3.29](/filings/0001048695-26-000067.md) | not reported | [3.12](/filings/0001048695-26-000023.md) | [2.61](/filings/0001048695-26-000051.md) | [3.67](/filings/0001048695-26-000067.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [797](/filings/0001048695-24-000185.md) | [823](/filings/0001048695-24-000012.md) | [903](/filings/0001048695-24-000079.md) | [935](/filings/0001048695-24-000125.md) | [1,075](/filings/0001048695-25-000157.md) | [1,151](/filings/0001048695-25-000026.md) | [1,259](/filings/0001048695-25-000091.md) | [1,427](/filings/0001048695-25-000129.md) | [1,344](/filings/0001048695-26-000067.md) | [1,200](/filings/0001048695-26-000023.md) | [1,443](/filings/0001048695-26-000051.md) | [1,606](/filings/0001048695-26-000067.md) |
| Current assets | $m | [1,849](/filings/0001048695-24-000185.md) | [1,962](/filings/0001048695-24-000012.md) | [1,952](/filings/0001048695-24-000079.md) | [1,986](/filings/0001048695-24-000125.md) | [2,109](/filings/0001048695-25-000157.md) | [2,342](/filings/0001048695-25-000026.md) | [2,336](/filings/0001048695-25-000091.md) | [2,485](/filings/0001048695-25-000129.md) | [2,519](/filings/0001048695-26-000067.md) | [2,515](/filings/0001048695-26-000023.md) | [2,703](/filings/0001048695-26-000051.md) | [2,947](/filings/0001048695-26-000067.md) |
| Total assets | $m | [5,248](/filings/0001048695-24-000185.md) | [5,349](/filings/0001048695-24-000012.md) | [5,385](/filings/0001048695-24-000079.md) | [5,414](/filings/0001048695-24-000125.md) | [5,613](/filings/0001048695-25-000157.md) | [5,901](/filings/0001048695-25-000026.md) | [5,907](/filings/0001048695-25-000091.md) | [6,113](/filings/0001048695-25-000129.md) | [6,319](/filings/0001048695-26-000067.md) | [6,292](/filings/0001048695-26-000023.md) | [6,497](/filings/0001048695-26-000051.md) | [6,829](/filings/0001048695-26-000067.md) |
| Current liabilities | $m | [1,473](/filings/0001048695-24-000185.md) | [1,524](/filings/0001048695-24-000012.md) | [1,502](/filings/0001048695-24-000079.md) | [1,456](/filings/0001048695-24-000125.md) | [1,490](/filings/0001048695-25-000157.md) | [1,588](/filings/0001048695-25-000026.md) | [1,524](/filings/0001048695-25-000091.md) | [1,551](/filings/0001048695-25-000129.md) | [1,613](/filings/0001048695-26-000067.md) | [1,619](/filings/0001048695-26-000023.md) | [1,677](/filings/0001048695-26-000051.md) | [1,770](/filings/0001048695-26-000067.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [0.0](/filings/0001048695-23-000039.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [2,800](/filings/0001048695-25-000157.md) | [2,861](/filings/0001048695-25-000091.md) | [2,933](/filings/0001048695-25-000129.md) | [3,011](/filings/0001048695-25-000129.md) | [3,129](/filings/0001048695-26-000067.md) | [3,236](/filings/0001048695-26-000051.md) | [3,314](/filings/0001048695-26-000067.md) | [3,472](/filings/0001048695-26-000067.md) | [3,592](/filings/0001048695-26-000067.md) | [3,538](/filings/0001048695-26-000051.md) | [3,650](/filings/0001048695-26-000067.md) | [3,856](/filings/0001048695-26-000067.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [190 d](/filings/0001048695-25-000157.md) | [165](/filings/0001048695-25-000026.md) | [222 d](/filings/0001048695-25-000091.md) | [159 d](/filings/0001048695-25-000129.md) | [247 d](/filings/0001048695-25-000157.md) | [203](/filings/0001048695-26-000023.md) | [257 d](/filings/0001048695-26-000051.md) | [282 d](/filings/0001048695-26-000067.md) | [208 d](/filings/0001048695-25-000157.md) | [159](/filings/0001048695-26-000023.md) | [366 d](/filings/0001048695-26-000051.md) | [316 d](/filings/0001048695-26-000067.md) |
| Capital expenditure | $m | [15.4 d](/filings/0001048695-25-000157.md) | [9.0](/filings/0001048695-25-000026.md) | [9.5 d](/filings/0001048695-25-000091.md) | [5.8 d](/filings/0001048695-25-000129.md) | [6.1 d](/filings/0001048695-25-000157.md) | [8.1](/filings/0001048695-26-000023.md) | [10.5 d](/filings/0001048695-26-000051.md) | [8.5 d](/filings/0001048695-26-000067.md) | [16.1 d](/filings/0001048695-25-000157.md) | [9.7](/filings/0001048695-26-000023.md) | [18.3 d](/filings/0001048695-26-000051.md) | [35.6 d](/filings/0001048695-26-000067.md) |
| Share repurchases | $m | [60.0 d](/filings/0001048695-25-000157.md) | [150](/filings/0001048695-24-000012.md) | [100 d](/filings/0001048695-25-000091.md) | [150 d](/filings/0001048695-25-000129.md) | [101 d](/filings/0001048695-25-000157.md) | not reported | not reported | [125 d](/filings/0001048695-26-000067.md) | [125 d](/filings/0001048695-25-000157.md) | not reported | not reported | [100 d](/filings/0001048695-26-000067.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [60.4](/filings/0001048695-24-000012.md) | [60.7](/filings/0001048695-24-000079.md) | [60.3](/filings/0001048695-24-000125.md) | [59.7](/filings/0001048695-25-000026.md) | [59.6](/filings/0001048695-25-000091.md) | [59.1](/filings/0001048695-25-000129.md) | [59.1](/filings/0001048695-26-000023.md) | [58.8](/filings/0001048695-26-000051.md) | [58.5](/filings/0001048695-26-000067.md) | [58.2](/filings/0001048695-26-000023.md) | [57.3](/filings/0001048695-26-000051.md) | [57.6](/filings/0001048695-26-000067.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 56,627,182 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001048695-26-000067.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.